The search strategy terms to identify studies relevant to the present review. by Brooke R. Brisbine (14197451)

Subjects:

Methodological overview of the 16 studies included in the present review. by Brooke R. Brisbine (14197451)

Subjects:

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. by Xueqin lu (22250795)

Subjects:

Sample size estimation based on preliminary date. by Jacquelyn Y. Taylor (6386456)

Subjects:

Cross-lagged panel model consistency test based on physical activity, aggressive behavior and Chinese language learning. by Zixia Bu (21475019)

Subjects:

Voxel based analyses for fractional anisotropy (FA) and apparent diffusion coefficient (ADC) detected increased FA and decreased ADC in trained reachers relative to controls. by Alexandra Badea (352052)

Estimated detected and non-detected colorectal cancer rates and their clinical stages based on colorectal cancer screening in Minamisoma City in 2011. by Hiroaki Saito (24514)

Subjects:

DataSheet1_Physiologically Based Pharmacokinetic Modeling in Pregnant Women Suggests Minor Decrease in Maternal Exposure to Olanzapine.docx by Liang Zheng (206933)

Effects of EMAP on experience of IPV by subgroups of physical IPV experience at baseline. by Alev Gurbuz Cuneo (14762002)

Subjects:

Effects of EMAP on experience of IPV by subgroups of sexual IPV experience at baseline. by Alev Gurbuz Cuneo (14762002)

Subjects:

GTDE effectively reduced d-gal-induced oxidative stress and increased the expression levels of antioxidant proteins and BDNF. by Hui-Chuan Kuo (12368492)

Dynamic stability based on the Feasible Stability Region (FSR). by Hyung Suk Yang (20442438)

Subjects:

Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

Subjects:

Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

Subjects:

Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects: